

# Biophytis to attend The Galien MedStartUp 2019 Event in New York

Paris (France), Cambridge (Massachusetts, United States), October 21, 2019, 5:30pm CEST - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of drug candidates for the treatment of age-related diseases, with a primary focus on neuromuscular diseases, announced today that management will participate in The Galien MedStartUp 2019 Event, which will take place on the 23<sup>rd</sup> and 24<sup>th</sup> of October 2019 in New York City. The event is organized jointly by the Galien Foundation and Business France. Biophytis will be available for one-to-one investor and global partnership meetings.

\*\*\*

#### **About Biophytis**

Biophytis is a clinical-stage biotechnology company focused on developing therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Biophytis' lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule, which is currently in a Phase 2b clinical trial for sarcopenia (SARA-INT) in the US and Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne muscular dystrophy (DMD). Biophytis expects Sarconeos (BIO101) to be ready to enter the clinic for DMD in 2020, subject to regulatory approval. Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts.

The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit <a href="https://www.biophytis.com">www.biophytis.com</a>.


#### Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on Biophytis' website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Biophytis in any country. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, Biophytis undertakes no obligation to update or revise the information contained in this press release. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

#### **Biophytis Investor Relations Contact**

Daniel Schneiderman, CFO



## Press Release

dan.schneiderman@biophytis.com Tel: +1 (857) 220-9720

### U.S. Media Contact

LifeSci Public Relations Cherilyn Cecchini, M.D. ccecchini@lifescipublicrelations.com

Tel: +1 (646) 876-5196

## **Europe Media Contact**

Citigate Dewe Rogerson Sylvie Berrebi / Quentin Dussart / Nathaniel Dahan / David Dible biophytis@citigatedewerogerson.com Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571

Source: Biophytis